"When the doctor told me she suspected it might be Parkinson's, I responded, 'That can't be right. I don’t even tremble." Today, on World Parkinson’s Day, we’re honored to share Lina’s story – an intimate and honest glimpse into the daily reality of living with this complex condition.
This year’s Nobel Prize in Physiology or Medicine recognizes the discovery of microRNAs. These small RNA molecules are central to Neumirna Therepeutics approach to developing treatments for neurological diseases.
A new review article based on the work led by Clara Mayer and Lluís Riera-Ponsati from Neumirna Therepeutics has been published in Frontiers in Pharmacology.
This substantial funding will be allocated to advance Neumirna's groundbreaking disease-modifying therapy for epilepsy to the clinic, bringing hope to the circa 50 million patients affected by epilepsy worldwide.
Henrik Klitgaard (Co-Founder, PhD) and Stine Norman-Hansen (Senior Scientist, PhD) authored this topical review together with leading pain expert, Prof. Lars Arendt-Nielsen.
This grant from the Innovation Fund Denmark (IFD) will help us in further establishing our drug discovery pipeline, aimed at developing disease-modifying RNA Therapies for Parkinson's Disease at NEUmiRNA, in collaboration with Aalborg University and the Center for RNA Medicine (CRM).
The project, conducted in collaboration with Motac Neuroscience and the Center for RNA Medicine at Aalborg University, aims to accelerate the development of disease-modifying treatments targeting microRNAs in Parkinson’s disease.
In 2021, Neumirna was selected and awarded by the US Epilepsy Foundation as being a promising start-up to advance new treatments for people with epilepsy in the EVF global accelerator course for start-up companies.
